diabetestalk.net

EnteroMedics Announces Publication Of Three-Year Data From VBloc Diabetic Patient Study In Journal Of Diabetes And Obesity

EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

ST. PAUL, Minn., Feb. 9, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of three-year data from the Company's VBLOC DM2 Study of vBloc® Neurometabolic Therapy in obese patients with Type 2 diabetes. The publication, entitled "Vagal Nerve Block for Improvements in Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus: Three-Year Results of the VBLOC DM2 Study," was published in the Journal of Diabetes and Obesity and is available online here.
"In addition to maintaining weight loss over time, successful management of comorbid conditions such as diabetes is critical," said Charles Billington, M.D., Professor, Department of Medicine, University of Minnesota. "The three-year data from the VBLOC DM2 study continue to demonstrate that vBloc Therapy not only provides durable improvements in weight loss through three years, but also improved glycemic control in obese patients with Type 2 diabetes who do not wish to undergo anatomy-altering weight-loss procedures."
Results from the study demonstrate that after three years, the average percentage excess weight loss (%EWL) was 21% with reductions in hemoglobin A1c (HbA1c) of 0.6 percentage points from a baseline of 7.8%. This clinically meaningful reduction in HbA1c resulted in 39% of participants either reducing or stopping their diabetes medications. Additionally, 71% of study participants were at or below the American Diabetes Association target for Hb Continue reading

Rate this article
Total 1 ratings
Is there a relationship between vitamin D with insulin resistance and diabetes mellitus?

Is there a relationship between vitamin D with insulin resistance and diabetes mellitus?


Is there a relationship between vitamin D with insulin resistance and diabetes mellitus?
Kamal AS Al-Shoumer, Division of Endocrinology and Metabolic Medicine, Department of Medicine, Faculty of Medicine, Kuwait University, 13110 Safat, Kuwait
Kamal AS Al-Shoumer, Thamer M Al-Essa, Division of Endocrinology and Metabolic Medicine, Department of Medicine, Mubarak Al Kabeer Hospital, 46304 Jabriya, Kuwait
Author contributions: Both authors contributed to this work.
Correspondence to: Kamal AS Al-Shoumer, MD, FRCP, PhD, FACE, Professor and Consultant, Head, Division of Endocrinology and Metabolic Medicine, Department of Medicine, Faculty of Medicine, Kuwait University, PO Box 24923, 13110 Safat, Kuwait. [email protected]
Telephone: +965-25-319596 Fax: +965-25-313511
Received 2014 Dec 7; Revised 2015 Apr 17; Accepted 2015 May 5.
Copyright The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
This article has been cited by other articles in PMC.
Available data suggest a possible link between abnormal vitamin D level and abnormal glucose homeostasis, two of the most common chronic medical conditions. Both conditions are associated with inflammation, and the exact mechanism for role of either on the other is not well clear. Literature investigating the link between vitamin D and either pre-diabetic states or diabetes is reviewed. Vitamin D deficiency is detrimental to insulin synthesis and secretion in animal and human studies. In humans, it has been shown by majority of observational studies, that vitamin D is positively correlated wit Continue reading

India’s Diabetes Epidemic Shifts to Poorer People in More Affluent Cities

India’s Diabetes Epidemic Shifts to Poorer People in More Affluent Cities

The Indian Council of Medical Research – India Diabetes (ICMR-INDIAB) study is the largest nationally representative study of diabetes in India and includes data from 57000 people across 15 states. As part of the study, each person had their body weight, height, waist circumference and blood pressure measured. Glucose tolerance tests were used to diagnose diabetes and pre-diabetes.
The prevalence of diabetes across all 15 states was 7.3% and rates varied from 4.3% in Bihar to 13.6% in Chandigarh. Almost half of the people in the study did not know they had diabetes until they were tested.
On average, diabetes was twice as common in urban areas (11.2%) compared to rural areas (5.2%). Overall, diabetes was more common among people with higher socio-economic status, compared to people with low socio-economic status. However, in urban areas in seven states – most of which rank among the more economically advanced states – diabetes was higher among people from low socio-economic status.
For example, in urban areas of Chandigarh, the rate of diabetes was 26.9% for among people from a low socio-economic background, compared to 12.9% for people from high socio-economic backgrounds. In urban areas of Punjab, the rates were 16.1% and 11.9% respectively.
Additionally, the rates of diabetes in rural areas were much higher than those identified in previous studies. The authors note that since 70% of the population in India lives in rural areas, even small increases can translate into several million more people requiring chronic care in areas with poor access to health care.
“Ou Continue reading

Everything You Need To Know About Diabetes Clinical Trials

Everything You Need To Know About Diabetes Clinical Trials


Consent form and information sheet detailing benefits, risks and compensation for participation
Different types of Diabetes Clinical trials
TrialNet is an international platform for clinical trials in type 1 diabetes with multiple trials conducted at once under a collaborative umbrella. The platform consists of 18 Clinical Centers spread throughout the globe with participation from about 100 Affiliates as collaborating clinical sites.3
Type 1 Diabetes There are numerous ongoing trials with the most recent one by ViaCyte Inc. which is a private company in regenerative medicine.4 The company has recently launched first phase of clinical trial for a stem-cell derived product candidate (VC-01) developed using two technologies: stem cell combined with an innovative delivery device called Encaptra used to deliver a dose of cells in various body locations. 4
Type 2 Diabetes This is an NIH-funded type 2 diabetes trial focusing on patients already on metformin medication. The trial is known as GRADE and involves assigning randomized participants to 1-4 commonly used glucose-lowering drugs plus metformin and followed for 7 years.5 The goal is to find the optimal combination of diabetes drugs for good glycemic control in long-term treatment of type 2 diabetes populations.5
Type 1 Diabetes During early stages of type 1 diabetes, up to 40% of pancreas cells make insulin which can still contribute to blood sugar control. For the first time in the world, a collaborative UK research team is using a peptide with memory to test the safety of a human vaccine for type 1 diabetes.6
Ty Continue reading

Do you have diabetes? These health insurance plans can help

Do you have diabetes? These health insurance plans can help


Do you have diabetes? These health insurance plans can help
Kunal, a young IT professional in his mid-30s was recently diagnosed with Type II Diabetes Mellitus . He did his homework about the long term and short-term implications of his latest condition. He was advised to walk regularly, exercise and curb the sugar intake in his diet. These are some of the measures his physician say are necessary to protect his heart, eyes and legs which prime casualties in diabetes patients in the long-term.
According to the International Diabetes Federation (IDF) website, diabetes is growing at alarming levels in India; more than 65 million people suffer from it presently and this figure is estimated to cross the 100 million mark by 2030. The usual suspects which lead to this condition are decreased physical activity, increased consumption of fat, sugar and calories, and higher stress levels affecting insulin sensitivity and obesity.
A friend of Kunals advised him to get a health insurance to cover the costs of any medical emergencies or procedures required in the future. Kunal was smart enough to heed the advice and called myinsuranceclub.com helpline, shortly after. So, lets see what kind of health insurance plans are available for people with his condition.
Diabetes health insurance market in India
If you want to buy a health insurance plan and are suffering from diabetes, it will qualify as a pre-existing condition and will be subject to a specified waiting period (usually a few years) as per the policy terms and conditions. In the worst case, insurer can deny the policy to yo Continue reading

No more pages to load

Popular Articles

Related Articles